[Neuroleptic malignant syndrome-dopamine-serotonin syndrome--the physiopathology, diagnosis, and therapy].
Naito
Y
Y
D000818:Animals; D001067:Appetite Depressants / Q000009:adverse effects; D003620:Dantrolene / Q000627:therapeutic use; D065127:Dopamine D2 Receptor Antagonists; D005277:Fenfluramine / Q000009:adverse effects; D006801:Humans; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy / Q000209:etiology; D011619:Psychotropic Drugs / Q000009:adverse effects; D012701:Serotonin / Q000378:metabolism*; D018490:Serotonin Agents / Q000009:adverse effects; D012702:Serotonin Antagonists / Q000009:adverse effects; D013577:Syndrome
D001067:Appetite Depressants; D065127:Dopamine D2 Receptor Antagonists; D009125:Muscle Relaxants, Central; D011619:Psychotropic Drugs; D018490:Serotonin Agents; D012702:Serotonin Antagonists; D005277:Fenfluramine; D012701:Serotonin; D003620:Dantrolene; D018817:N-Methyl-3,4-methylenedioxyamphetamine